Home›Diabetes & Endocrinology› Retatrutide Shifts Fatty Acid Oxidation and Insulin Resistance Metabolites in Obesity Trials
Retatrutide Shifts Fatty Acid Oxidation and Insulin Resistance Metabolites in Obesity TrialsNew drug retatrutide shows promise for weight loss and diabetes
The Journal of clinical endocrinology and metabolismPublished October 22, 2026Study authors: Pearson Mackenzie J, Willency Jill A, Lin Yanzhu, Abadi Arkan, Hartman Mark L, Coskun Tamer, Ruotolo…PubMed ↗DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Retatrutide shifted fatty acid oxidation and insulin resistance metabolites, which mediated up to 23% of weight loss in phase 2 trials.
This post hoc exploratory analysis of two phase 2 randomized trials examined how retatrutide, a multi-agonist incretin therapy, affects circulating metabolites in people living with obesity, with and without type 2 diabetes. The obesity trial enrolled 282 participants over 36 weeks; the diabetes trial enrolled 213 over 48 weeks. Participants received retatrutide at 0.5, 1, 4, 8, or 12 mg, with placebo or dulaglutide 1.5 mg as comparators.
Higher retatrutide doses were associated with changes in a cluster of metabolites reflecting fatty acid oxidation, including 3-hydroxybutyrate, acetylcarnitine, free carnitine, and fatty acid-derived long-chain acylcarnitines. A second cluster linked to insulin resistance also shifted with treatment in both populations; this included branched-chain amino acids and their catabolic products, 2-aminoadipic acid, 2-hydroxybutyrate, urate, and triglycerides enriched in short-chain and saturated acyl side chains.
Mediation analysis suggested that the fatty acid oxidation metabolites contributed to weight reduction, explaining 23.2% of the effect in participants without type 2 diabetes and 12.7% in those with type 2 diabetes. The authors frame these shifts as moving in a direction consistent with improved metabolic health and lower cardiovascular risk, though the analysis was not designed to test clinical outcomes.
Safety, tolerability, and discontinuation data were not reported in this abstract, and funding sources were not disclosed. As a post hoc exploratory analysis of phase 2 trials, the findings are hypothesis-generating; the biomarker changes and mediation estimates should not be interpreted as proven improvements in metabolic health or reduced cardiovascular risk.
How this fits prior evidence
How this fits prior evidence: This finding addresses a gap in the understanding of metabolic pathways influenced by novel GLP-1RAs. While prior coverage noted that SGLT-2is and GLP-1RAs significantly reduce heart failure related composite endpoints in type 2 diabetes, this study explores the specific metabolic mechanisms, such as fatty acid oxidation and insulin resistance, associated with retatrutide. It also provides a different perspective on metabolic markers compared to the finding that structured exercise reduces triglycerides and LDL-C in adults with type 2 diabetes.
Managing weight and type 2 diabetes involves more than just the number on the scale. It involves complex internal processes like how the body handles fats and insulin. Researchers looked at a new medication called retatrutide to see how it affects these internal markers in people living with obesity.
The study followed two groups: one with obesity and one with both obesity and type 2 diabetes. They found that higher doses of retatrutide were linked to changes in a group of metabolites. These are substances in the body that help break down fats and improve how the body handles sugar. Specifically, the drug was linked to changes in markers associated with insulin resistance.
While the results suggest the drug may help improve metabolic health, it is important to note that this was an exploratory analysis of a phase 2 trial. This means the data is still early and the researchers are looking for patterns rather than making final claims. More research is needed to confirm how well this works over a long period.
What this means for you:
Retatrutide is linked to changes in blood markers that help the body process fat and manage insulin resistance.
Common questions
What is retatrutide and how does it work?
Retatrutide is a medication being studied for people with obesity and type 2 diabetes. In this study, it was linked to changes in two groups of metabolites. These are substances in the blood that help the body break down fats and manage insulin, which is the hormone that controls blood sugar.
Who can benefit from this new treatment?
This study included participants living with obesity, both with and without type 2 diabetes. The results showed that retatrutide was associated with changes in markers related to insulin resistance in both groups. Talk to your doctor to see if this treatment is right for your specific health needs.
Is this treatment proven to be safe?
Because this was a phase 2 trial and an exploratory analysis, the full safety profile is not yet fully established. The study did not report specific side effects or how well the drug was tolerated by patients. You should always consult a medical professional regarding the safety of any new medication.
CONTEXT: In phase 2 trials, retatrutide reduced body weight, hemoglobin A1c and improved the lipid profiles of participants living with obesity, with and without T2D.
OBJECTIVE: Assess plasma metabolome and lipidome changes associated with retatrutide treatment.
METHODS: Metabolomics and lipidomics were performed in fasting samples from 2 randomized, placebo-controlled phase 2 trials as a post hoc exploratory analysis. Participants living with obesity with and without T2D were treated for 36 and 48 weeks, respectively. There were 282 and 213 participants in the obesity and T2D trials, respectively and the intervention(s) received were: Obesity trial: retatrutide (1, 4, 8, and 12 mg) or placebo; T2D trial: retatrutide (0.5, 4, 8, and 12 mg) or placebo or dulaglutide (1.5 mg). The main outcome measure(s) were changes in metabolite and lipid levels with retatrutide treatment against baseline levels and placebo using multiplicity correction.
RESULTS: At both primary and study endpoints for both populations, higher doses of retatrutide were associated with changes in a cluster of metabolites comprising 3-hydroxybutyrate, acetylcarnitine, free carnitine, and fatty acid-derived long-chain acylcarnitines. Mediation analyses suggested that changes in these biomarkers mediated 23.2% of the weight reduction response in participants without T2D and that this mediation was blunted to 12.7% in participants with T2D. Retatrutide treatment was also associated with changes in metabolites associated with insulin resistance, including branched-chain amino acids and their catabolic products, 2-aminoadipic acid, 2-hydroxybutyrate, urate, and triglycerides enriched in short-chain and saturated acyl side chains. These changes were found in both study populations and sustained across study endpoints.
CONCLUSION: Retatrutide was associated with changes in 2 metabolic clusters related to fatty acid oxidation and insulin resistance in a direction associated with improved metabolic health and reduced cardiovascular risk.
